<?xml version='1.0' encoding='utf-8'?>
<document id="29969029"><sentence text="De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors."><entity charOffset="56-98" id="DDI-PubMed.29969029.s1.e0" text="3,4-Disubstituted Pyrrolidine Sulfonamides" /><entity charOffset="123-130" id="DDI-PubMed.29969029.s1.e1" text="Glycine" /><pair ddi="false" e1="DDI-PubMed.29969029.s1.e0" e2="DDI-PubMed.29969029.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29969029.s1.e0" e2="DDI-PubMed.29969029.s1.e1" /></sentence><sentence text="The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor"><entity charOffset="19-26" id="DDI-PubMed.29969029.s2.e0" text="glycine" /><entity charOffset="178-198" id="DDI-PubMed.29969029.s2.e1" text="N-methyl-d-aspartate" /><entity charOffset="200-204" id="DDI-PubMed.29969029.s2.e2" text="NMDA" /><pair ddi="false" e1="DDI-PubMed.29969029.s2.e0" e2="DDI-PubMed.29969029.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29969029.s2.e0" e2="DDI-PubMed.29969029.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29969029.s2.e0" e2="DDI-PubMed.29969029.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29969029.s2.e1" e2="DDI-PubMed.29969029.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29969029.s2.e1" e2="DDI-PubMed.29969029.s2.e2" /></sentence><sentence text=" Herein, we describe the synthesis and biological evaluation of a series of 3,4-disubstituted pyrrolidine sulfonamides as competitive GlyT1 inhibitors that arose from de novo scaffold design"><entity charOffset="76-118" id="DDI-PubMed.29969029.s3.e0" text="3,4-disubstituted pyrrolidine sulfonamides" /></sentence><sentence text=" Relationship of chemical structure to drug-drug interaction (DDI) and bioactivation was mechanistically investigated" /><sentence text=" Murine studies were strategically incorporated into the screening funnel to provide early assessments of in vivo target occupancy (TO) by ex vivo binding studies" /><sentence text=" Advanced compounds derived from iterative structure-activity relationship (SAR) studies possessed high potency in ex vivo binding studies and good brain penetration, promising preliminary in vivo efficacy, acceptable preclinical pharmacokinetics, and manageable DDI and bioactivation liabilities" /><sentence text="" /></document>